Nautilus Biotechnology (NAUT) Competitors $2.34 +0.10 (+4.46%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NAUT vs. TNYA, BCAB, AFMD, ORIC, TRNS, CTKB, EYPT, LAB, QTRX, and AEHRShould you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Tenaya Therapeutics (TNYA), BioAtla (BCAB), Affimed (AFMD), ORIC Pharmaceuticals (ORIC), Transcat (TRNS), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Quanterix (QTRX), and Aehr Test Systems (AEHR). Nautilus Biotechnology vs. Tenaya Therapeutics BioAtla Affimed ORIC Pharmaceuticals Transcat Cytek Biosciences EyePoint Pharmaceuticals Standard BioTools Quanterix Aehr Test Systems Nautilus Biotechnology (NASDAQ:NAUT) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation. Is NAUT or TNYA more profitable? Nautilus Biotechnology's return on equity of -28.85% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nautilus BiotechnologyN/A -28.85% -24.93% Tenaya Therapeutics N/A -86.17%-71.14% Which has better valuation & earnings, NAUT or TNYA? Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNautilus BiotechnologyN/AN/A-$63.67M-$0.56-4.18Tenaya TherapeuticsN/AN/A-$124.08M-$1.44-1.54 Does the MarketBeat Community believe in NAUT or TNYA? Tenaya Therapeutics received 28 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 80.00% of users gave Tenaya Therapeutics an outperform vote while only 20.00% of users gave Nautilus Biotechnology an outperform vote. CompanyUnderperformOutperformNautilus BiotechnologyOutperform Votes420.00% Underperform Votes1680.00% Tenaya TherapeuticsOutperform Votes3280.00% Underperform Votes820.00% Does the media favor NAUT or TNYA? In the previous week, Tenaya Therapeutics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 0 mentions for Nautilus Biotechnology. Tenaya Therapeutics' average media sentiment score of 0.43 beat Nautilus Biotechnology's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nautilus Biotechnology Neutral Tenaya Therapeutics Neutral Which has more volatility and risk, NAUT or TNYA? Nautilus Biotechnology has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500. Do institutionals & insiders hold more shares of NAUT or TNYA? 50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 40.5% of Nautilus Biotechnology shares are held by insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend NAUT or TNYA? Nautilus Biotechnology presently has a consensus price target of $4.50, suggesting a potential upside of 92.31%. Tenaya Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 564.41%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Nautilus Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nautilus Biotechnology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTenaya Therapeutics beats Nautilus Biotechnology on 10 of the 15 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Nautilus Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAUT vs. The Competition Export to ExcelMetricNautilus BiotechnologyAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$293.82M$5.09B$5.06B$8.82BDividend YieldN/A0.46%5.18%4.07%P/E Ratio-4.1823.87126.3217.81Price / SalesN/A4.391,179.2574.56Price / CashN/A40.7033.8632.53Price / Book1.102.084.684.68Net Income-$63.67M$515,312.50$119.54M$226.08M7 Day Performance-4.88%-5.56%-1.83%-1.04%1 Month Performance-15.52%-8.12%-3.60%1.04%1 Year Performance-13.33%-17.04%31.91%26.28% Nautilus Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAUTNautilus Biotechnology1.7398 of 5 stars$2.34+4.5%$4.50+92.3%-15.8%$293.81MN/A-4.18130TNYATenaya Therapeutics3.9769 of 5 stars$2.15-3.2%$14.75+586.0%+18.4%$170.32MN/A0.00110Gap UpBCABBioAtla2.8165 of 5 stars$1.46-1.4%$6.00+311.0%-11.4%$70.59M$250,000.000.0060Short Interest ↓AFMDAffimed3.2493 of 5 stars$2.85+4.8%$16.00+461.4%-42.7%$45.89M$8.95M0.0076Analyst ForecastORICORIC Pharmaceuticals4.1915 of 5 stars$8.72-0.2%$18.29+109.7%+22.4%$615.37MN/A-4.8680Analyst RevisionTRNSTranscat2.9676 of 5 stars$102.83-1.4%$127.25+23.7%+7.5%$946.04M$259.48M51.931,104Positive NewsCTKBCytek Biosciences2.884 of 5 stars$6.07-1.0%$9.17+51.0%+0.8%$781.88M$193.01M0.00500Short Interest ↓News CoverageEYPTEyePoint Pharmaceuticals2.2894 of 5 stars$8.95flat$28.00+212.8%+26.6%$610.84M$46.02M0.00120LABStandard BioTools3.2166 of 5 stars$1.61+6.6%$2.88+78.6%-29.1%$599.34M$106.34M0.00620QTRXQuanterix2.4285 of 5 stars$10.85-1.5%$23.25+114.3%-52.5%$416.42M$122.37M0.00460AEHRAehr Test Systems2.1758 of 5 stars$11.31+0.4%$25.00+121.0%-56.6%$335.12M$66.22M11.5090 Related Companies and Tools Related Companies TNYA Competitors BCAB Competitors AFMD Competitors ORIC Competitors TRNS Competitors CTKB Competitors EYPT Competitors LAB Competitors QTRX Competitors AEHR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NAUT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAUT Stock Alerts